Oramed starts second late-stage study of insulin capsule; shares rise

Oramed Pharmaceuticals

23/03/2021 14:55

** Drug developer's shares  ORMP.O  rise 6.9% to $11.10
    ** Co says started a second late-stage study of its oral
insulin capsule, ORMD-0801, for the treatment of type 2 diabetes
 urn:newsml:reuters.com:*:nPn4D4K5la     
    ** Co to recruit 450 patients with type 2 diabetes through
28 sites in U.S. and 25 sites in Western Europe and Israel for
this study
    ** Says both studies are taking place under U.S. FDA
protocols, and that enrollment for the other Phase 3 study has
crossed 25%
    ** ORMP stock up ~159% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))